Ascendis Pharma A/S
ASND
25 hedge funds and large institutions have $185M invested in Ascendis Pharma A/S in 2015 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 5 closing their positions.
17% more capital invested
Capital invested by funds: $158M → $185M (+$26.9M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
4% less funds holding
Funds holding: 26 → 25 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$18.3M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$3.68M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$1.23M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$865K |
| 5 |
SCM
Sio Capital Management
New York
|
+$263K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VM
VHCP Management
New York
|
-$12.6M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$1.72M |
| 3 |
AIC
AWM Investment Company
New York
|
-$1.39M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.19M |
| 5 |
Lazard Asset Management
New York
|
-$303K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIC
26
AWM Investment Company
New York
| – | -$1.39M | -78,540 | Closed |
|
|
27
Alyeska Investment Group
Chicago,
Illinois
| – | -$1.19M | -67,079 | Closed |
|
|
PAM
28
Panagora Asset Management
Boston,
Massachusetts
| – | -$27K | -1,503 | Closed |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| – | -$3K | -175 | Closed |
|
30
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$631 | -36 | -86% |
|
ASND Hedge Fund Activity: Q4 2015 in Review
25 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q4 2015, worth a combined $185M — up 17% from $158M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ASND and 4 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 7 added.
The largest buyer was Fidelity Investments, adding an estimated $18.3M. The largest seller was VHCP Management, cutting an estimated $12.6M.
- 25 institutional investors held Ascendis Pharma A/S (ASND) as of Q4 2015, down from 26 in Q3 2015.
- Funds reported $185M of Ascendis Pharma A/S stock for Q4 2015, up 17% quarter-over-quarter.
- 4 funds opened new Ascendis Pharma A/S positions in Q4 2015 and 5 closed out, a net change of -1 holder.
- The largest Ascendis Pharma A/S buyer in Q4 2015 was Fidelity Investments, an estimated $18.3M added.
- The largest Ascendis Pharma A/S seller in Q4 2015 was VHCP Management, an estimated $12.6M sold.
Based on aggregated 13F filings for Q4 2015.